Latest Sorafenib Stories

Penn Medicine study shows drug stops tumor growth and provides the first effective treatment for thyroid cancer patients who progress following standard therapies The kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo, according to results of a randomized phase III trial, which will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a...

Data to be Presented at Plenary Session at Annual Meeting of the American Society of Clinical Oncology WAYNE, N.J. and SOUTH SAN FRANCISCO, Calif., June 2, 2013 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced positive results from the Phase 3 DECISION trial investigating the use of Nexavar(®) (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid...

NEW YORK, May 18, 2013 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO). (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses on whether the Company and its executives violated federal securities laws by issuing materially false and/or misleading statements regarding the Company's Phase III drug...

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Intended for U.S. Media Only -- Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar® (sorafenib) tablets, Stivarga® (regorafenib) tablets and the recently U.S. Food and Drug Administration (FDA) approved product Xofigo® (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 31 - June 4, in Chicago, IL (USA). These data...

WAYNE, N.J., May 15, 2013 /PRNewswire/ -- Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga(®) (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on Nexavar(®) (sorafenib) tablets, an anticancer medicine for the treatment of patients with...

New scoring system defines patients who achieve most benefit from TACE Data from a number of clinical trials presented today at the International Liver Congress™ 2013 shed new light on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC). Transarterial chemoembolization (TACE) is a technique in which small particles designed to block blood vessels mixed or coated with chemotherapeutic drugs are injected directly into an artery supplying the tumor; it has become...

Now Enrolling Patients into Third Dosing Cohort SAN MARINO, Calif., April 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. (OTC Pink: VGLS), a biotechnology company focused on leveraging its innovative platform technologies for the discovery and development of drug therapies for cancer, infectious disease, and inflammation, announced today positive results from stage two of its Pre-IND Phase I Study to test tolerability and toxicity in patients with advanced stage solid tumors. The...

NORTHBROOK, Ill., Feb. 13, 2013 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced that more than 10 abstracts from Astellas oncology pipeline agents and marketed products will be presented at the 2013 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU), to be held February 14-16 in Orlando, Florida. "We're committed to delivering new treatment options for patients with GU...

BURLINGTON, Mass., Feb. 4, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through 2021, the treatment landscape for thyroid carcinoma will change dramatically in the United States and Europe due to the expected approval of several new therapies. In addition to Exelixis's Cometriq (cabozantinib) for advanced medullary thyroid carcinomas (MTC)--which was approved in the U.S. late...

BURLINGTON, Mass., Jan. 29, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the treatment landscape for hepatocellular carcinoma in the United States and Europe will change dramatically through 2021 as three new, potentially high priced therapies-Novartis's Afinitor, ArQule's tivantinib and Celsion's ThermoDox-arrive on the market, thereby greatly increasing treatment...